Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics of high-dose busulfan in children

  • 88 Accesses

  • 83 Citations


The pharmacokinetics of high-dose busulfan given orally at 1 mg/kg every 6 h over 4 days (total dose, 16 mg/kg) in combined chemotherapy followed by autologous bone marrow transplantation was studied in 12 children with a mean age of 7 years (range, 4–14 years). Busulfan levels in biological fluids were measured by a gas chromatographic assay with mass fragmentographic detection, using a deuterated analogue as the internal standard. In a high-dose regimen, busulfan followed one-compartment model kinetics with zero-order absorption. A mean maximal concentration of 803±228 ng/ml was achieved at 92–255 min after dosing. The mean elimination half-life was 2.33 h, and the mean total clearance was 119±54 ml/min per m2, with an apparent distribution volume of 27.10±11.50 l/m2. A mean trough level of 370 ng/ml was found throughout the 4 days of the chemotherapy course. There were no significant variations in pharmacokinetic parameters measured after the first and last doses. Busulfan was monitored in the CSF of nine children at 3.25–7 h after the last dose and was detected in all patients, with a mean CSF-to-plasma concentration ratio of 0.95 (range, 0.5–1.4).

This is a preview of subscription content, log in to check access.


  1. 1.

    Baillie TA, Rettenmeier AW (1986) Recent advances in the use of stable isotopes in drug metabolism research. J Clin Pharmacol 26:481

  2. 2.

    Bishop JB, Wassom JS (1986) Toxicological review of busulfan (Myleran). Mutat Res 168: 15

  3. 3.

    Blazar BR, Ramsay NKC, Kersey JH,Krivit W, Arthur DC, Filipovich AH (1985) Pretransplant conditioning with busulphan (Myleran) and cyclophosphamide for non malignant diseases. Transplantation 39: 597

  4. 4.

    Borsi JD, Moe PJ (1987) A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 60: 5

  5. 5.

    Ehrsson H, Hassan M (1983) Determination of busulfan in plasma by GC-MS with selected-ion monitoring. J Pharm Sci 72: 1203

  6. 6.

    Ehrsson H, Hassan M,Ehrnebo M, Beran M (1983) Busulfan kinetics. Clin Pharmacol Ther 34:86

  7. 7.

    Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184

  8. 8.

    Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C, Flamant F, Lemerle J (1986) High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 4: 1804

  9. 9.

    Hassan M, Ehrsson H (1983) Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 277: 374

  10. 10.

    Henner WD, Furlong EA, Flaherty MD, Shea TC (1987) Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 416: 426

  11. 11.

    Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJC, Williamson S (1986) Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1: 201

  12. 12.

    Klein PD, Klein ER (1986) Stable isotopes: origin and safety. J Clin Pharmacol 26: 378

  13. 13.

    Lin KH, Lin KS, Feig SA (1986) Marrow transplantation for thalassemia. Bone Marrow Transplant 1: 115

  14. 14.

    Lu C, Braine HG, Kayzer H, Saral R, Tutschka PJ, Santos GW (1984) Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 68: 711

  15. 15.

    Marcus RE, Goldman JM (1984) Convulsions due to high-dose busulfan. Lancet II: 1463

  16. 16.

    Odaimi M, Ajani J (1987) High-dose chemotherapy: concepts and strategies. J Clin Oncol 10: 123

  17. 17.

    Parkman R, Rappeport JM, Hellman S, Lipton J, Smith B, Geha R, Nathan DG (1984) Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. Blood 64: 852

  18. 18.

    Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart RK, Yeager AM (1983) Marrow transplantation for acute non lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347

  19. 19.

    Shumaker RC (1986) PKCalc: a basic interactive computer program of statistical and pharmacokinetic analysis of data. Drug Metab Rev 17: 331

  20. 20.

    Vassal G, Re M, Gouyette A (1988) Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr Biomed Appl 428: 357

Download references

Author information

Correspondence to A. Gouyette.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Vassal, G., Gouyette, A., Hartmann, O. et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother. Pharmacol. 24, 386–390 (1989).

Download citation


  • Pharmacokinetic Parameter
  • Bone Marrow Transplantation
  • Marrow Transplantation
  • Biological Fluid
  • Trough Level